|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Multivariate analysis further showed that moderate/strong ATF2 expression and phospho-ATF2 positivity were independent predictors for recurrence of low-grade tumors (hazard ratio (HR) = 2.956, P = 0.045) and cancer-specific mortality of muscle-invasive tumors (HR = 5.317, P = 0.012), respectively.
|
30521479 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Activating transcription factor 2 (ATF2) is a multifunctional transcription factor, and is implicated in tumor progress, yet its role in pancreatic cancer remains unclear.
|
28318081 |
2017 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Moreover, ATF2 was shown to be highly expressed in RCC tissues, especially in tumors with metastases.
|
27377902 |
2016 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The mitochondrial accumulation of ATF2 is involved in tumor suppressor activities via cytochrome c release in melanoma cells.
|
26462148 |
2015 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Notably, nuclear ATF2 and low expression of IFNβ1 in melanoma tumor samples correlates with poor patient responsiveness to biochemotherapy or neoadjuvant IFN-α2a.
|
25728676 |
2015 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activating transcription factor-2 (ATF-2) has been implicated as a tumour suppressor in breast cancer (BC). c-JUN N-terminal kinase (JNK) and p38 MAPK phosphorylate ATF-2 within the activation domain (AD), which is required for its transcriptional activity.
|
25141981 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we show ATF2 suppresses tumor formation in an orthotopic model of liver cancer and cellular transformation in vitro.
|
25456131 |
2014 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Herein we perform immunohistochemical analyses using a validated specific antibody for ATF2 expression and intracellular localization on a cohort of 594 malignant and 207 benign mesenchymal tumors representing 47 diagnostic entities.
|
24289970 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Oxidative stress and MAPK involved into ATF2 expression in immortalized human urothelial cells treated by arsenic.
|
23591579 |
2013 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activating transcription factor 2 (ATF2; also known as cAMP-dependent transcription factor ATF-2) has oncogenic activities in melanoma and tumor suppressor activities in non-malignant skin tumors and breast cancer.
|
22685333 |
2012 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover nuclear factor (NF)-κB and other transcription factors like CREB, ATF-2 involved in tumour development and angiogenesis were also inhibited by harmine.
|
20858484 |
2010 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The transcription factor ATF2 has been shown to attenuate melanoma susceptibility to apoptosis and to promote its ability to form tumors in xenograft models.
|
21203491 |
2010 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Yet work in other tumor models, including breast and skin tumors reveals that ATF2, in cooperation with mutated oncogenes or tumor suppressor genes, can also elicit tumor suppressor function.
|
18677098 |
2008 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These studies suggest the functional link between the ATF-2 and the two tumor suppressors BRCA1 and p53.
|
17700520 |
2008 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, ATF-2 acts as a tumor susceptibility gene of mammary tumors, at least partly, by activating a group of target genes, including Maspin and Gadd45alpha.
|
17189429 |
2007 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To assess the role of the ATF-2 gene as a tumor suppressor in human carcinogenesis, we examined genetic alterations of the ATF-2 gene in 9 breast cancer cell lines, 10 neuroblastoma cell lines and 46 lung cancer cell lines.
|
11836564 |
2002 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results suggest that ATF2 is a regulator of radiation and drug resistance in melanomas, and that tumor targeted ATF2 modulators may be useful sensitizers in the treatment of tumors of this type.
|
9484842 |
1998 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the levels of CRE-BP1 mRNA in some clinical samples of human tumors were apparently higher than that in normal tissues.
|
1829805 |
1991 |
|
Malignant Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
In this review, we summarise the current understanding of the underestimated 'cancer gene chameleon' ATF2 in apoptosis, epithelial-to-mesenchymal transition and microRNA regulation and highlight its functions in CRC and pancreatic cancer.
|
31799611 |
2019 |
|
Malignant Neoplasms
|
0.370 |
AlteredExpression
|
group |
BEFREE |
Overall, these findings provide scientific evidence that miR657 is an onco-miRNA targeting the ER stress signal pathway and SSD induces apoptosis via the inhibition of miR-657, ROS, and the activation of p-ATF2 and CHOP as a potent anti-cancer agent for myeloid-originated hematological cancer.
|
30696076 |
2019 |
|
Malignant Neoplasms
|
0.370 |
AlteredExpression
|
group |
BEFREE |
Thus, ATF2 appears to be activated in urothelial cells through the AR pathway and promotes the development and progression of urothelial cancer.
|
30521479 |
2018 |
|
Malignant neoplasm of breast
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
In summary, the variant alleles of TSG101 rs2292179 and ATF2 rs3845744 were associated with a reduced risk of breast cancer, particularly for subjects with BMI <24 (kg/m(2)) and postmenopausal women, respectively.
|
26729199 |
2016 |
|
Malignant Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
The purpose of the present study was to investigate whether ATF2 may have a role in acquired resistance to cisplatin in non-small cell lung cancer (NSCLC). mRNA and protein analysis on matched cancer and corresponding normal tissues from surgically resected NSCLC have been performed.
|
25359574 |
2015 |
|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
While expression of ATF-2 is not associated with outcome, pATF-2 is associated with longer disease-free (p = 0.002) and BC-specific survival in patients exposed to tamoxifen (p = 0.01).
|
25141981 |
2014 |
|
Malignant Neoplasms
|
0.370 |
Biomarker
|
group |
CTD_human |
ATF2 has been implicated in a transcriptional response leading to cell migration and malignant tumor progression.
|
23591579 |
2013 |